vidarabine has been researched along with Atrial Fibrillation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suzumiya, J; Takizawa, J | 1 |
| Ando, K; Cao, X; Izumi-Nakaseko, H; Nakamura, Y; Nakazato, Y; Ohara, H; Sugiyama, A; Wada, T | 1 |
1 review(s) available for vidarabine and Atrial Fibrillation
| Article | Year |
|---|---|
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Vidarabine | 2020 |
1 other study(ies) available for vidarabine and Atrial Fibrillation
| Article | Year |
|---|---|
Antiviral drug vidarabine possessing cardiac type 5 adenylyl cyclase inhibitory property did not affect cardiohemodynamic or electrophysiological variables in the halothane-anesthetized dogs.
Topics: Adenylyl Cyclase Inhibitors; Anesthesia, Inhalation; Animals; Antiviral Agents; Atrial Fibrillation; Dogs; Electrophysiological Phenomena; Halothane; Heart Failure; Hemodynamics; Infusions, Intravenous; Male; Models, Animal; Vidarabine | 2016 |